News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Direvo Biotech AG Announces Validation of bestMab(TM)


5/6/2008 11:02:48 AM

COLOGNE, GERMANY--(Marketwire - May 06, 2008) - DIREVO Biotech AG announced today that it has validated its "bestMab™" platform through the generation of an optimized version of the anti-inflammatory antibody, Adalimumab (Humira®), with unprecedentedly strong binding properties. optiMIRA™ shows 300-times tighter antigen binding than Humira®, and more than 15- fold tighter binding than the previously most advanced optimized Humira® derivative, which was generated using display technology. The results of this study were presented on May 1st, 2008 at the Fourth Annual Protein Engineering Summit (PEGS) conference in Boston, USA. The presentation can be viewed at www.direvo.com/bestMab/PEGS

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES